Edesa Biotech Empfehlungs-Mittelwert
Was ist das Empfehlungs-Mittelwert von Edesa Biotech?
Empfehlungs-Mittelwert von Edesa Biotech, Inc. ist 2.00
Was ist die Definition von Empfehlungs-Mittelwert?
Der empfohlene Mittelwert ist der Durchschnitt der Analystenbewertungen der Aktie von 1,0 (starker Kauf) bis 5,0 (starker Verkauf).
Mean of recommendations is an average of ratings from different analysts but it should still be used with other research and investment metrics in order to make investment decisions. It is important to understand a firm's entire scale when assimilating ratings. Additionally, analyst recommendations on stocks owned by firms employing them may be seen as potentially biased.
Financial analysts are often employed by mutual and pension funds, hedge funds, securities firms, banks, investment banks, insurance companies, and other businesses, helping these companies or their clients make investment decisions. Financial analysts employed in commercial lending perform "balance sheet analysis," examining the audited financial statements and corollary data in order to assess lending risks. In a stock brokerage house or in an investment bank, they read company financial statements and analyze commodity prices, sales, costs, expenses, and tax rates in order to determine a company's value and project future earnings. In any of these various institutions, the analyst often meets with company officials to gain a better insight into a company's prospects and to determine the company's managerial effectiveness.
Usually, financial analysts study an entire industry, assessing current trends in business practices, products, and industry competition. They must keep abreast of new regulations or policies that may affect the industry, as well as monitor the economy to determine its effect on earnings.
Empfehlungs-Mittelwert von Unternehmen in Health Care Sektor auf NASDAQ im Vergleich zu Edesa Biotech
Was macht Edesa Biotech?
Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical treatment that is in Phase 2B clinical study for chronic allergic contact dermatitis. It has a license agreement with NovImmune SA to develop monoclonal antibodies targeting TLR4 and CXCL10. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.
Unternehmen mit empfehlungs-mittelwert ähnlich Edesa Biotech
- Cabot Oil & Gas hat Empfehlungs-Mittelwert von 1.96
- Truist hat Empfehlungs-Mittelwert von 1.96
- Delta Air Lines hat Empfehlungs-Mittelwert von 1.96
- Discover Services hat Empfehlungs-Mittelwert von 1.96
- United Micro Electronics hat Empfehlungs-Mittelwert von 1.96
- Tapestry Inc hat Empfehlungs-Mittelwert von 1.97
- Edesa Biotech hat Empfehlungs-Mittelwert von 2.00
- Trip.com Ltd hat Empfehlungs-Mittelwert von 2.03
- Sherwin-Williams Co hat Empfehlungs-Mittelwert von 2.03
- Canadian Pacific Kansas City hat Empfehlungs-Mittelwert von 2.03
- Arista Networks Inc hat Empfehlungs-Mittelwert von 2.03
- Anheuser-Busch InBev SA/NV hat Empfehlungs-Mittelwert von 2.03
- Celanese Corp hat Empfehlungs-Mittelwert von 2.04